Letrozolo Sandoz

Letrozole, the active ingredient in Letrozolo Sandoz, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, where it reduces estrogen production that can fuel tumor growth.

GNH USA supplies Letrozolo Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution through its dedicated regulatory team.

Letrozolo Sandoz, an aromatase inhibitor, is indicated for hormone‑dependent breast cancer.

- Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen levels to inhibit tumor growth. - Early‑stage hormone receptor‑positive breast cancer (adjuvant): Decreases risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: Delays disease progression in advanced disease.

Letrozolo Sandoz may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Arthralgia or myalgia. - Fatigue: Generalized tiredness. - Nausea: Mild to moderate upset stomach. - Headache: Tension‑type or migraine‑like pain. - Increased cholesterol: Elevated LDL levels.

Serious or Rare Side Effects: - Osteoporosis or bone fractures: Decreased bone mineral density. - Severe liver injury: Elevated transaminases or hepatitis. - Cardiovascular events: Thromboembolic episodes. - Allergic reactions: Rash, pruritus, or anaphylaxis. - Hyperglycemia: Elevated blood glucose levels.

When prescribing Letrozolo Sandoz, clinicians should consider several precautionary measures to minimise risk.

- Assess bone health: Perform baseline densitometry and monitor for osteoporosis. - Monitor lipid profile: Check cholesterol levels periodically. - Evaluate liver function: Conduct baseline and periodic liver enzyme tests. - Consider cardiovascular risk: Review history of thromboembolic disease. - Counsel on menopausal symptoms: Discuss management of hot flashes and sweating. - Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture.

Letrozolo Sandoz can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May markedly reduce letrozole plasma levels. - Estrogen‑containing hormone therapy: Counteracts the drug’s estrogen‑lowering effect.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): May increase letrozole exposure. - Anticoagulants (warfarin): Potential for altered INR, requiring monitoring. - Cholesterol‑lowering agents (statins): May have additive effects on liver enzymes. - Selective serotonin reuptake inhibitors (SSRIs): Possible impact on hot‑flash management.